Company / Return on Equity (ROE)
Edesa Biotech, Inc. Return on Equity (ROE) History
FY2014-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-96.0%
FY2021
5-year range
-96.0% / -23.1%
FY2017-FY2021
Trend
-81.6%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Edesa Biotech, Inc. reports negative total equity of -96.0% in FY2021. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-96.0% in FY2021 with a 3-year CAGR of -28.0%.
Declined from -68.0% to -96.0% over the past 3 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -28.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2021, return on equity (roe) decreased 81.6% year-over-year.
- Peak return on equity (roe) was recorded in FY2017.
- Lowest return on equity (roe) in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2021 | -96.0% | -81.6% |
| FY2020 | -52.8% | +22.3% |
| FY2018 | -68.0% | -194.5% |
| FY2017 | -23.1% | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | -612.9% | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026